Health Care • Biopharmaceuticals, GLP-1/GIP Cardiometabolic & Oncology • SIC 2834
$1,417.54 ▲ +43.84
(+3.19%)
MKT CAP: $1.34T • VOL: 5.03M
52W L $810 52W H $1,450
CONSENSUS RATING DISTRIBUTION (36 DESKS)
BUY: 31 HOLD: 4
SELL: 1
12M STREET TARGET RANGE
IMPLIED: +19.2%
LOW
$1,473
MEDIAN
$1,687
MEAN
$1,690
HIGH
$1,824
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
82/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE LLY TAPE
LLY // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
2026-10-01
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| UBS AJ Rice | REITERATE | OUTPERFORM | $1,586.30 | $1,443.53 | 2026-04-24 | $883.96 | +60.4% | 96% | A+ |
| Jefferies Akash Tewari | TARGET REV | OUTPERFORM | $1,654.34 | $1,505.45 | 2026-03-27 | $878.24 | +61.4% | 96% | A+ |
| Citigroup Peter Verdult | UPGRADE | STRONG BUY | $1,708.21 | $1,554.47 | 2026-05-22 | $1,065.00 | +33.1% | 93% | A+ |
| Bernstein SocGen Group Courtney Breen / Lance Wilkes | REITERATE | OUTPERFORM | $1,637.33 | $1,489.97 | 2026-06-18 | $1,098.57 | +29.0% | 90% | A+ |
| Morgan Stanley Terence Flynn | UPGRADE | STRONG BUY | $1,784.76 | $1,624.13 | 2026-09-11 | $1,115.70 | +27.1% | 85% | A |
| Evercore ISI Umer Raffat | TARGET REV | STRONG BUY | $1,764.91 | $1,606.07 | 2026-07-31 | $1,148.84 | +23.4% | 85% | A |
| Bank of America Securities Tim Anderson / Kevin Fischbeck | UPGRADE | STRONG BUY | $1,798.93 | $1,637.03 | 2026-08-28 | $1,174.61 | +20.7% | 83% | A |
| J.P. Morgan Chris Schott / Lisa Gill | TARGET REV | OUTPERFORM | $1,665.68 | $1,515.77 | 2026-07-17 | $1,179.11 | +20.2% | 79% | A |
| Goldman Sachs Chris Shibutani | UPGRADE | STRONG BUY | $1,824.45 | $1,660.25 | 2026-08-14 | $1,180.16 | +20.1% | 78% | A |
| Barclays Carter Gould / Andrew Mok | DOWNGRADE | UNDERPERFORM | $1,472.90 | $1,340.34 | 2026-02-27 | $1,051.99 | +34.8% | 35% | F |